Lung Cancer

The FDA has granted an approval to the combination of atezolizumab (Tecentriq) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

Pembrolizumab was granted a priority review to treat patients with advanced small-cell lung cancer whose disease progressed on 2 or more lines of prior therapy.

The FDA granted a priority review to entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

An expert goes over the common – and not-so-common – immune-related adverse events.

In a presentation during the 16th Annual Winter Lung Conference™, Gregory J. Riely, MD, PhD, discussed the spectrum of activity of many of these FDA-approved EGFR TKIs.

A recent meta-analysis has found no noticeable difference in immunotherapy's efficacy based on patient sex.

The FDA has expanded the indication for pemetrexed (Alimta) injection in combination with pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.

The FDA has accepted a supplemental biologics license application (sBLA) for atezolizumab (Tecentriq), carboplatin, and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

Half of patients diagnosed with advanced non-small cell lung cancer were alive 6.8 years after diagnosis, according to new study findings.

The FDA has approved the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel (ABCP) for the frontline treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). This indication excludes patients with EGFR/ALK aberrations.

The FDA has granted a priority review designation to atezolizumab (Tecentriq) for use in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

A surprising cancer demographic warrants increased attention and support.

The acceptance of next-generation sequencing (NGS) platforms and cell-free DNA (cfDNA) have enabled oncologists to more specifically target genetic mutations in the treatment of patients with non–small cell lung cancer (NSCLC), according to Benjamin P. Levy, MD.

Because of the risk for developing secondary malignancies, and given the association between smoking and cancer, all patients who smoke should be counseled about quitting, according to Linda Sarna, PhD, RN, FAAN.

The PD-1 inhibitor pembrolizumab (Keytruda) has shown an overall survival advantage across 3 phase III clinical trials studying its use in patients with metastatic non–small cell lung cancer (NSCLC). These positive results led to a frontline indication as a single agent and in combination with chemotherapy for both patients with squamous and nonsquamous NSCLC.

Choosing frontline therapy for patients with metastatic non–small cell lung cancer (NSCLC) who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology, according to Gregory J. Riely, MD, PhD.

Scientists, physicians and patients collaborate to improve treatment for rare cancer.

Frontline alectinib (Alecensa), a next-generation tyrosine kinase inhibitor, enabled Asian patients with untreated ALK-positive advanced non–small cell lung cancer (NSCLC) to live significantly longer without disease progression compared with those who were treated with crizotinib (Xalkori) as initial therapy.

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinases inhibitors (TKIs).

The FDA has approved pembrolizumab (Keytruda) for first-line use in combination with carboplatin and either paclitaxel or nab-paclitaxel (Abraxane) for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

The FDA has added 3 months to the review period for

Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory, and anxiety.

Brigatinib (Alunbrig) reduced the risk of disease progression or death by more than 50% compared to crizotinib (Xalkori) in adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.

The FDA has approved the pan-human EGFR tyrosine kinase inhibitor (TKI) dacomitinib (Vizimpro) for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations in the frontline setting.

In combination with the standard front-line chemotherapy regimen of carboplatin and etoposide, the addition of atezolizumab (Tecentriq) significantly prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

The Society for Immunotherapy of Cancer (SITC) announced a new partnership to raise awareness of and participation in the Lung Cancer Registry, an initiative led by research and patient advocacy organizations, the Bonnie J. Addario Lung Cancer Foundation (ALCF), American Lung Association’s LUNG FORCE and the International Association for the Study of Lung Cancer.

The Bonnie J. Addario Lung Cancer Foundation (ALCF) is partnering with ALK Positive, an online community of over 1,200 members worldwide dealing with ALK-positive lung cancer, to encourage Lung Cancer Registry membership.

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.